去年初，公司完成对中山海济（后更名为"圣湘海济"）的全资收购，正式切入健康消费赛道，成为战略 从诊断向治疗延伸的关键里程碑。2026年2月，其产品人生长激素注射液（海之元®）拟新增用于特发 性矮身材（ISS）的适应症补充申请获得国家药监局的临床试验批准，后续圣湘海济将启动ISS适应症Ⅲ 期临床试验，将助力公司优化业务结构、完善战略产品线布局、增强核心竞争力。 此外，通过控股红岸基元、受让股权并增资真迈生物，圣湘生物进一步强化在基层医疗检测与基因科技 上游领域的行业话语权；增资圣维鲲腾、直接参股圣维斯睿，加速布局多重分子POCT、脓毒症诊断等 临床前沿检测场景。2026年1月，公司持续深化全球布局，控股收购全球HLA诊断与血液分子诊断领军 企业德国inno-train Diagnostik GmbH，显著提升在输血安全、器官移植等国内高门槛细分领域的竞争力 与行业领导力。 本报讯 2月27日晚间，圣湘生物发布2025年度业绩快报，报告期内公司实现营业收入16.48亿元，同比增 长13.04%；归母净利润1.98亿元，扣非净利润1.65亿元。公司凭借"诊疗一体化"战略的深度落地，通过 技术突破、外延并购、全球布局 ...

Core Insights - The conference showcased Shengxiang Biotechnology's breakthroughs in medical digitization and its innovative technologies that inject new momentum into the global healthcare industry [1][6] Group 1: AI and Technology Innovations - Shengxiang's advanced product development manager introduced AI-driven automation in PCR testing, enhancing the Taq enzyme's interference resistance, achieving 100% detection effectiveness in complex samples, validated by over 2 million clinical data [2] - The company implemented a three-tier resource allocation algorithm using a combination of rule engines and machine learning, optimizing patient triage across hospitals, communities, and home settings, thus reducing costs and time for patients [2] Group 2: Comprehensive Detection Solutions - Shengxiang launched multiple disruptive products to establish a comprehensive detection system covering hospitals, grassroots, and home settings [3] - The molecular intelligent detection assembly line offers automated, unattended processing, enabling immediate testing and multi-sample analysis, enhancing hospital testing efficiency [3] - The FASTASeq 300 high-throughput gene sequencer, a domestic desktop sequencing platform, provides advantages in versatility, speed, and cost, making precise gene testing accessible to county-level medical institutions [3] Group 3: Advanced POCT Products - The Q-POC 2.0 product focuses on severe infection detection, delivering results within 30 minutes with a detection limit of 250 copies/mL, crucial for urgent patient care [4] - The SUREXEVO series, the world's first AI-based molecular POCT product, supports parallel detection of multiple pathogens, significantly improving respiratory disease testing efficiency [4] Group 4: Collaborative Ecosystem Development - Shengxiang collaborates with industry partners like Meituan and JD Health to create a comprehensive detection service ecosystem covering testing, diagnosis, medication, and management [5] - The company initiated a project to enhance infectious disease control capabilities in county and community healthcare, aiming to establish a collaborative system for initial screening, precise diagnosis, and health management [6]

Core Viewpoint - The company, Shengxiang Bio, aims to establish a comprehensive detection system covering "hospitals - grassroots - families" through the launch of multiple products, leveraging AI technology to achieve "medical equity" [1][5]. Product Launch and Technology - Shengxiang Bio introduced the world's first AI-based molecular POCT product, the SUREXEVO series, which features 16 independent modules for parallel testing and can detect seven pathogens in one tube using eight-color fluorescence technology, significantly reducing detection time from four hours to 13 minutes and 40 seconds [5]. - The AI-enhanced enzyme technology used in the SUREXEVO series has demonstrated 100% detection effectiveness in complex samples, validated by over 2 million clinical data instances [5]. - The company plans to expand its technology to blood sample testing and aims to lead global PCR technology [5]. Comprehensive Detection System - Shengxiang Bio released various devices to meet different scenario needs, including molecular intelligent detection lines, FASTASeq300 high-throughput gene sequencers, portable multifunctional detection analyzers, and Q-POC2.0 ultra-multiplex molecular POCT products, all contributing to the establishment of a full-scene detection system [5]. - The Q-POC2.0 product focuses on critical infection detection, providing results within 30 minutes and a detection limit as low as 250 copies/mL, which is crucial for emergency patient treatment [6]. Future Plans and Collaborations - The company announced plans to launch the SUREXSTM unattended testing platform within the year, aiming to create an integrated service capability for "offline instant testing, online diagnosis and prescription, and immediate drug delivery" [6]. - This platform will be developed in collaboration with industry partners such as Meituan and JD Health, forming a comprehensive testing service ecosystem [6]. Financial Performance and R&D Investment - Recent half-year reports indicate stable revenue growth for Shengxiang Bio, with R&D investment reaching 154 million yuan, accounting for 17.71% of revenue [7]. - The company has obtained over 100 new domestic and international registration certificates and has accumulated more than 1,700 certifications, alongside the addition of over 70 new patents and software copyrights [7].